U.S., June 14 -- ClinicalTrials.gov registry received information related to the study (NCT07019675) titled 'A Study of SKB518 in Patients With Lung Cancer' on June 05.
Brief Summary: This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB518 in patients with lung cancer. Eligible subjects will receive SKB518 monotherapy, until radiographic disease progression, intolerable toxicity, discontinuation of study treatment required by the subject, or other protocol-specified treatment discontinuation criteria, whichever occurs first.
Study Start Date: June 20
Study Type: INTERVENTIONAL
Condition:
Lung Carcinoma
Intervention:
DRUG: SKB51...